Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension (Q36272405)

13 August 2017

Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension (English)

1 reference

13 August 2017

arterial hypertension

0 references

17

Fernando Torres

1 reference

13 August 2017

Paul M Hassoun

1

1 reference

13 August 2017

Roham T Zamanian

2

1 reference

13 August 2017

Rachel Damico

3

1 reference

13 August 2017

Noah Lechtzin

4

1 reference

13 August 2017

Rubina Khair

5

1 reference

13 August 2017

Todd M Kolb

6

1 reference

13 August 2017

Ryan J Tedford

7

1 reference

13 August 2017

Olivia L Hulme

8

1 reference

13 August 2017

Traci Housten

9

1 reference

13 August 2017

Chiara Pisanello

10

1 reference

13 August 2017

Takahiro Sato

11

1 reference

13 August 2017

Erica H Pullins

12

1 reference

13 August 2017

Celia P Corona-Villalobos

13

1 reference

13 August 2017

Stefan L Zimmerman

14

1 reference

13 August 2017

Mohamed A Gashouta

15

1 reference

13 August 2017

Omar A Minai

16

1 reference

13 August 2017

Reda E Girgis

18

1 reference

13 August 2017

Kelly Chin

19

1 reference

13 August 2017

Stephen C Mathai

20

1 reference

13 August 2017

language of work or name

English

0 references

publication date

11 September 2015

1 reference

American Journal of Respiratory and Critical Care Medicine

13 August 2017

1 reference

13 August 2017

192

1 reference

13 August 2017

9

1 reference

13 August 2017

1102-1110

1 reference

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Noninvasive imaging in the assessment of the cardiopulmonary vascular unit

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Effect of pulmonary arterial hypertension-specific therapies on health-related quality of life: a systematic review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Definitions and diagnosis of pulmonary hypertension.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Pulmonary capillary wedge pressure augments right ventricular pulsatile loading.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Increased right ventricular Septomarginal trabeculation mass is a novel marker for pulmonary hypertension: comparison with ventricular mass index and right ventricular mass

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Changes in causes of death in systemic sclerosis, 1972-2002

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Pulmonary arterial hypertension in France: results from a national registry

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Sildenafil citrate therapy for pulmonary arterial hypertension

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Measuring the heart in pulmonary arterial hypertension (PAH): implications for trial study size

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Sildenafil for pulmonary arterial hypertension associated with connective tissue disease

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Updated Clinical Classification of Pulmonary Hypertension

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Tadalafil therapy for pulmonary arterial hypertension.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Clinical differences between idiopathic and scleroderma-related pulmonary hypertension

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Tricuspid annular displacement predicts survival in pulmonary hypertension

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4642204

Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study

22 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1164%2FRCCM.201507-1398OC

Evaluation of Pulmonary Artery Stiffness in Pulmonary Hypertension With Cardiac Magnetic Resonance

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1164%2FRCCM.201507-1398OC

Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1164%2FRCCM.201507-1398OC

Quantification of right ventricular afterload in patients with and without pulmonary hypertension

21 January 2018

1 reference

12 December 2020

Bosentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension

1 reference

12 December 2020

Connective Tissue Disease–associated Pulmonary Arterial Hypertension in the Modern Treatment Era

1 reference

12 December 2020

Ventricular mass index correlates with pulmonary artery pressure and predicts survival in suspected systemic sclerosis-associated pulmonary arterial hypertension

1 reference

12 December 2020

Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure

1 reference

12 December 2020

10.1164/RCCM.201507-1398OC

Identifiers

DOI

1 reference

13 August 2017

1 reference

13 August 2017

1 reference